Equities

BrightGene Bio-Medical Technology Co Ltd

688166:SHH

BrightGene Bio-Medical Technology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)36.80
  • Today's Change1.97 / 5.66%
  • Shares traded13.28m
  • 1 Year change+69.98%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BrightGene Bio-Medical Technology Co Ltd is a China-based company mainly engaged in the research, development and production of generic drugs and original new drugs. The Company's main products include antifungal active pharmaceutical ingredients (APIs), antiviral APIs, immunosuppressive APIs, and other APIs and preparations. The Company's generic drugs mainly include entecavir, caspofungin, micafungin, posaconazole, everolimus and fondaparinux sodium. The Company mainly conducts its businesses in domestic and overseas markets.

  • Revenue in CNY (TTM)1.16bn
  • Net income in CNY233.79m
  • Incorporated2001
  • Employees1.13k
  • Location
    BrightGene Bio-Medical Technology Co LtdBuilding C25-28, No.218 Xinghu Road, SipSUZHOU 215123ChinaCHN
  • Phone+86 51 262620988
  • Fax+86 51 262551799
  • Websitehttps://www.bright-gene.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Mabwell Shanghai Bioscience Co Ltd191.35m-1.02bn13.25bn1.49k--5.51--69.25-2.55-2.550.47896.020.04120.047216.79128,337.60-22.02-37.61-26.37-45.9596.8481.54-534.78-2,112.261.96--0.442--361.0327.88-10.28--17.35--
Zhejiang CONBA Pharmaceutical Co., Ltd.6.43bn523.43m13.70bn8.41k26.381.92--2.130.2020.2022.492.780.55682.394.60764,058.905.026.777.2510.5054.3663.249.0211.101.5340.710.145942.3212.20-0.826765.20-6.21-11.645.92
Suzhou Zelgen Biopharmaceuticals Co Ltd386.57m-260.85m14.10bn867.00--8.85--36.48-1.00-1.001.496.020.16210.25943.75445,874.00-11.74-27.13-20.82-39.2092.2992.75-72.40-220.712.15--0.3842--27.83211.8139.08--41.38--
Henan Lingrui Pharmaceutical Co., Ltd.3.43bn614.24m14.21bn2.53k22.994.81--4.141.091.096.095.210.72462.0413.841,356,471.0012.9710.6821.2716.5671.7474.4217.9014.921.26--0.012272.8010.3110.0322.0918.49-16.4739.77
Zhejiang Jiuzhou Pharmaceutical Co Ltd5.25bn989.32m14.23bn4.88k14.341.63--2.711.101.105.849.690.45231.874.361,076,055.008.5210.1011.0713.6935.8034.6418.8316.262.07--0.181640.791.4424.2912.2045.7432.1420.11
Sunshine Guojian Pharmcutcl Shngh Co Ltd1.07bn352.22m14.61bn965.0041.472.93--13.600.5710.5711.748.090.20781.149.251,112,527.006.611.326.931.4177.8580.7431.816.556.66--0.018.2522.84-2.35497.63-4.4421.22--
BrightGene Bio-Medical Technology Co Ltd1.16bn233.79m14.71bn1.13k63.606.19--12.690.54770.54772.735.630.25631.593.181,028,270.004.658.295.679.9559.3158.0118.1321.311.755.320.472328.99-3.3326.28-1.7739.1854.07--
Liaoning Cheng Da Co Ltd11.18bn17.48m15.45bn3.36k776.920.5297--1.380.0130.0137.3419.070.23584.416.493,330,121.00-0.53663.59-0.76445.2116.0314.15-2.289.890.7792--0.283415.93-25.97-10.97-80.95-21.267.04--
Changchun BCHT Biotechnology Co1.92bn543.19m15.79bn1.24k29.013.86--8.241.321.324.649.880.41160.84591.551,543,550.0011.679.9514.1412.8189.9086.6328.3624.032.03--0.015810.5570.3012.36175.9831.3721.04--
Shanghai Shyndec Pharmaceutical Co Ltd11.78bn843.91m16.42bn11.61k19.141.29--1.390.63940.63948.959.480.60693.086.611,014,487.005.754.858.508.1737.0943.009.487.031.82--0.105717.52-6.861.2910.21-0.3897-2.210.00
Jiang Zhong Pharmaceutical Co Ltd4.30bn734.24m16.60bn4.01k22.624.02--3.861.171.176.836.550.66984.3413.621,071,799.0012.3510.8218.8215.0864.0165.0218.4418.171.47--0.006182.8813.0020.1218.408.5411.4740.99
Data as of May 17 2024. Currency figures normalised to BrightGene Bio-Medical Technology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

6.21%Per cent of shares held by top holders
HolderShares% Held
Harvest Fund Management Co., Ltd.as of 30 Jun 20238.55m2.09%
GF Fund Management Co., Ltd.as of 30 Jun 20237.72m1.88%
Hui'an Fund Management Co. Ltd.as of 30 Sep 20234.52m1.10%
The Vanguard Group, Inc.as of 05 Apr 20241.24m0.30%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 20231.13m0.28%
Lion Fund Management Co., Ltd.as of 30 Jun 2023963.07k0.24%
China Asset Management Co., Ltd.as of 30 Jun 2023425.41k0.10%
China Southern Asset Management Co., Ltd.as of 30 Jun 2023376.97k0.09%
Dimensional Fund Advisors LPas of 04 Apr 2024282.18k0.07%
China Universal Asset Management Co., Ltd.as of 30 Jun 2023256.93k0.06%
More ▼
Data from 30 Jun 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.